https://www.selleckchem.com/pr....oducts/gsk3326595-ep
3% vs 11.2%, p=0.043), younger at diagnosis (median 46 years vs 62 years, p less then 0.001) and more common at right-sided location (66.7% vs 23.1%; p=0.003). All patients with POLE EMDs were assessed as extremely high TMB, with a mean TMB of 200.8. Compared with other stage II CRCs, POLE EDMs displayed an enhanced intratumoral cytotoxic T cell response, evidenced by increased numbers of CD8+TILs and CD8A expression. Patients with stage II CRCs could be classified into three risk subsets, with significant different 5 years
Like
Comment
Share
